A retro-inverso α-melanocyte stimulating hormone analog with MC1R-binding selectivity

Journal of Peptide Science

Volumn 17, Issue 1, 2011, Pages 47-55

  Weeden, Timothy ^a   Stefano, Jim ^b   Duan, Su ^a   Edling, Andrea ^c   Hou, Lihui ^b   Chuang, Wei Lien ^b   Perricone, Michael A ^c   Pan, Clark ^b   Dzuris, John L ^a  

^a Transplant and Immunology Research   (United States)

^b GENZYME CORPORATION   (United States)

^c Immunotherapy Research   (United States)

Author keywords

Analog; Anti inflammatory; Autoimmunity; MSH; Peptide; Retro inverso

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; MELANOCORTIN 1 RECEPTOR; TETRAPEPTIDE;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; HUMAN; HUMAN CELL; MELANOMA CELL; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING;

ALPHA-MSH; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECEPTOR, MELANOCORTIN, TYPE 1;

EID: 78650247533     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1306     Document Type: Article

References (35)

1. Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J. Immunol. 2005; 175: 4806-4813.
2. Manna SK, Aggarwal BB. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J. Immunol. 1998; 161: 2873-2880.
3. Siebenlist U, Franzoso G, Brown K. Structure regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 1994; 10: 405-455.
4. Grossmann M, Nakamura Y, Grumont R, Gerondakis S. New insights into the roles of ReL/NF-kappa B transcription factors in immune function hemopoiesis and human disease. Int. J. Biochem. Cell Biol. 1999; 31: 1209-1219.
5. Rheins LA, Cotleur AL, Kleier RS, Hoppenjans WB, Saunder DN, Nordlund JJ. Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J. Invest. Dermatol. 1989; 93: 511-517.
6. Riemann H, Schwarz A, Grabbe S, Aragane Y, Luger TA, Wysocka M, Kubin M, Trinchieri G, Schwarz T. Neutralization of IL-12 in vivo prevents induction of contact hypersensitivity and induces hapten-specific tolerance. J. Immunol. 1996; 156: 1799-1803.
7. Kokot A, Sindrilaru A, Schiller M, Sunderkotter C, Kerkhoff C, Eckes B, Scharffetter-Kochanek K, Luger TA, Bohm M. Alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum. 2009; 60: 592-603.
8. Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM, Howles PN, Morgan DA, Benoit SC, Szanto I, Schrott B, Schurmann A, Joost HG, Hammond C, Hui DY, Woods SC, Rahmouni K, Butler AA, Farooqi IS, O'Rahilly S, Rohner-Jeanrenaud F, Tschop MH. The central melanocortin system directly controls peripheral lipid metabolism. J. Clin. Invest. 2007; 117: 3475-3488.
9. Marks DL, Butler AA, Cone RD. Melanocortin pathway: animal models of obesity and disease. Annu. Endocrinol. (Paris) 2002; 63: 121-124.
10. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr. Top. Med. Chem. 2007; 7: 1137-1144.
11. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, Cone RD. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997; 91: 789-798.
12. Ignar DM, Andrews JL, Jansen M, Eilert MM, Pink HM, Lin P, Sherrill RG, Szewczyk JR, Conway JG. Regulation of TNF-alpha secretion by a specific melanocortin-1 receptor peptide agonist. Peptides 2003; 24: 709-716.
13. Getting SJ. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol. Ther. 2006; 111: 1-15.
14. Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, Gao XB, Diament A, Haus KA, Shariat-Madar Z, Mahdi F, Wardlaw SL, Schmaier AH, Warden CH, Diano S. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J. Clin. Invest. 2009; 119: 2291-2303.
15. Todorovic A, Holder JR, Bauzo RM, Scott JW, Kavanagh R, Abdel-Malek Z, Haskell-Luevano C. N-terminal fatty acylated His-dPhe-Arg-Trp-NH(2) tetrapeptides: influence of fatty acid chain length on potency and selectivity at the mouse melanocortin receptors and human melanocytes. J. Med. Chem. 2005; 48: 3328-3336.
16. Koikov LN, Ebetino FH, Solinsky MG, Cross-Doersen D, Knittel JJ. Sub-nanomolar hMC1R agonists by end-capping of the melanocortin tetrapeptide His-D-Phe-Arg-Trp-NH(2). Bioorg. Med. Chem. Lett. 2003; 13: 2647-2650.
17. Szardenings M, Tornroth S, Mutulis F, Muceniece R, Keinanen K, Kuusinen A, Wikberg JE. Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1. J. Biol. Chem. 1997; 272: 27943-27948.
18. Szardenings M, Muceniece R, Mutule I, Mutulis F, Wikberg JE. New highly specific agonistic peptides for human melanocortin MC(1) receptor. Peptides 2000; 21: 239-243.
19. Muceniece R, Mutule I, Mutulis F, Prusis P, Szardenings M, Wikberg JE. Detection of regions in the MC1 receptor of importance for the selectivity of the MC1 receptor super-selective MS04/MS05 peptides. Biochim. Biophys. Acta 2001; 1544: 278-282.
20. Chorev M, Goodman M. A dozen years of retro-inverso peptidomimetics. Acc. Chem. Res. 1993; 26: 266-273.
21. Verdini AS, Viscomi GC. Synthesis, resolution, and assignment of configuration of potent hypotensive retro-inverso bradykinin potentiating peptide 5a(BPP5a) analogues. J. Chem. Soc., Perkin Trans. 1 1985; 14: 697-701.
22. Goodman M, Coddington J, Mierke DF, Fuller WD. Model for the sweet taste of stereoisomeric retro-inverso and dipeptide amides. J. Am. Chem. Soc. 1987; 109: 4712-4714.
23. Briand JP, Benkirane N, Guichard G, Newman JF, Van Regenmortel MH, Brown F, Muller S. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc. Natl. Acad. Sci. USA 1997; 94: 12545-12550.
24. Vunnam S, Juvvadi P, Rotondi KS, Merrifield RB. Synthesis and study of normal enantio retro and retroenantio isomers of cecropin A-melittin hybrids their end group effects and selective enzyme inactivation. J. Pept. Res. 1998; 51: 38-44.
25. Freidinger RM, Veber DF. Peptides and their retro enantiomers are topologically nonidentical. J. Am. Chem. Soc. 1979; 101: 6129-6131.
26. Bednarek MA, Silva MV, Arison B, MacNeil T, Kalyani RN, Huang RR, Weinberg DH. Structure-function studies on the cyclic peptide MT-II lactam derivative of alpha-melanotropin. Peptides 1999; 20: 401-409.
27. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg SA. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 1994; 153: 1225-1237.
28. Sahm UG, Olivier GW, Branch SK, Moss SH, Pouton CW. Synthesis and biological evaluation of alpha-MSH analogues substituted with alanine. Peptides 1994; 15: 1297-1302.
29. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. USA 1980; 77: 5754-5758.
30. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 1995; 312(Pt 3): 725-731.
31. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000; 43: 1664-1669.
32. Holder JR, Bauzo RM, Xiang Z, Haskell-Luevano C. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors: part 2 modifications at the Phe position. J. Med. Chem. 2002; 45: 3073-3081.
33. Haskell-Luevano C, Sawyer TK, Trumpp-Kallmeyer S, Bikker JA, Humblet C, Gantz I, Hruby VJ. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. Drug Des. Discov. 1996; 14: 197-211.
34. Schioth HB, Yook P, Muceniece R, Wikberg JE, Szardenings M. Chimeric melanocortin MC1 and MC3 receptors: identification of domains participating in binding of melanocyte-stimulating hormone peptides. Mol. Pharmacol. 1998; 54: 154-161.
35. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, Fritzberg AR, Winkelmann CT, Hoffman T, Quinn TP. Melanoma therapy via peptide-targeted {α}-radiation. Clin. Cancer Res. 2005; 11: 5616-5621.